ClinicalTrials.gg
Not yet recruitingNCT07951684SMILEUpdated Nov 20, 2026

Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE

An interventional study of Probiotic and placebo solution in Mucositis Oral and Head & Neck Cancer, sponsored by IRCCS San Raffaele. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by IRCCS San Raffaele · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.

02

Conditions studied

  • Mucositis Oral
  • Head & Neck Cancer

Keywords

  • oral mucositis
03

In context

Stomatitis

307 studies on the registry are indexed under Stomatitis; 73 are open to participants now.

This study's planned enrollment of 170 is above the median of 60 across 276 interventional studies indexed under Stomatitis.

Browse Stomatitis studies →

Lead sponsor

IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are willing and able to give for participation in the study.
  2. Aged >=18 years
  3. Patients diagnosed with non- head and neck malignant tumors, with an performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
  4. Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
  5. Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of allergy to probiotics or severe allergic constitution
  2. Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
  3. Poor oral hygiene and/or severe periodontal diseases ( 5.0 Grading >/=2)
  4. Any previous RT to the head and neck region
  5. Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
  6. Allergies: history of known allergies to probiotics or to product .
  7. Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
  8. Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
  9. Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
  10. Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
  11. Pregnancy and breastfeeding
  12. related to probiotic composition
  13. Primary sites different from the ones described in inclusion criteria
  14. Patient unfit to cisplatin
  15. Patients
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
170 participants (estimated)

Study arms

  • Placebo comparator
    placebo group

    The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria.

    Other: placebo solution

  • Experimental
    group treated with probiotic: Streptococcus salivarius Evol12®

    The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient. Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period.

    Other: Probiotic

Interventions

  • OtherProbiotic

    Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization.

  • Otherplacebo solution

    Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration

06

What researchers measure

Primary outcomes

  1. EORTC QLQ-H&N35 score

    Change in quality of life assessed using the EORTC QLQ-H\&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks.

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Secondary outcomes

  1. days

    Time to onset (days) of WHO grade ≥2 and ≥3.

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

  2. days

    Duration (days) of WHO grade ≥2 and ≥3.

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

  3. Percentage

    Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

  4. Numeric Rating Scale (NRS)

    Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

  5. Percentage

    Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%).

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

  6. days

    duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

    Time frame: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2027, 0 months later.

Of 66 non-industry interventional studies with no phase under Stomatitis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's planned 0 months is below that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 10 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951684
Lead sponsor
IRCCS San Raffaele
Responsible party
Aurora Mirabile (Medical oncologist, IRCCS San Raffaele) — Principal investigator
First posted
Nov 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Aurora Mirabile Medical oncologist
Contact
mirabile.aurora@hsr.it
+39 02 2643 3526

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion